lufotrelvir lufotrelvir lufotrelvir (pf-07304814) is an antiviral drug developed by pfizer which acts as a 3cl protease inhibitor. it is a prodrug with the phosphate group being cleaved in vivo to yield the active agent pf-00835231. lufotrelvir is in human clinical trials for the treatment of covid-19, and shows good activity against covid-19 including several variant strains, but unlike the related drug nirmatrelvir it is not orally active and must be administered by intravenous infusion, and so has been the less favoured candidate for clinical development overall. lufotrelvirlegal statuslegal status us: investigational drug identifiers iupac name -4-methylpentanamido]-2-oxo-4-butoxy]phosphonic acid cas number2468015-78-1pubchem cid154699467drugbankdb16514uniixj51yob1sckeggd12172chebichebi:173073chemical and physical dataformulac24h33n4o9pmolar mass552.521 g·mol−13d model (jsmol)interactive image smiles cc(c)c(c(=o)n(c1ccnc1=o)c(=o)cop(=o)(o)o)nc(=o)c2=cc3=c(n2)c=cc=c3oc inchi inchi=1s/c24h33n4o9p/c1-13(2)9-18(28-24(32)19-11-15-16(26-19)5-4-6-21(15)36-3)23(31)27-17(10-14-7-8-25-22(14)30)20(29)12-37-38(33,34)35/h4-6,11,13-14,17-18,26h,7-10,12h2,1-3h3,(h,25,30)(h,27,31)(h,28,32)(h2,33,34,35)/t14-,17-,18-/m0/s1key:fqkalofowpdted-wbaxxedzsa-n